AU2002302192B2 - Treatment and composition for wound healing - Google Patents

Treatment and composition for wound healing Download PDF

Info

Publication number
AU2002302192B2
AU2002302192B2 AU2002302192A AU2002302192A AU2002302192B2 AU 2002302192 B2 AU2002302192 B2 AU 2002302192B2 AU 2002302192 A AU2002302192 A AU 2002302192A AU 2002302192 A AU2002302192 A AU 2002302192A AU 2002302192 B2 AU2002302192 B2 AU 2002302192B2
Authority
AU
Australia
Prior art keywords
apc
agent
protein
wound
wound healing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2002302192A
Other languages
English (en)
Other versions
AU2002302192A1 (en
Inventor
Christopher John Jackson
Philip Neil Sambrook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZZ Biotech LLC
Original Assignee
ZZ Biotech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR5637A external-priority patent/AUPR563701A0/en
Priority claimed from AUPS1433A external-priority patent/AUPS143302A0/en
Application filed by ZZ Biotech LLC filed Critical ZZ Biotech LLC
Priority to AU2002302192A priority Critical patent/AU2002302192B2/en
Publication of AU2002302192A1 publication Critical patent/AU2002302192A1/en
Application granted granted Critical
Publication of AU2002302192B2 publication Critical patent/AU2002302192B2/en
Assigned to ZZ BIOTECH LLC reassignment ZZ BIOTECH LLC Request for Assignment Assignors: THE UNIVERSITY OF SYDNEY
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002302192A 2001-06-13 2002-06-11 Treatment and composition for wound healing Expired AU2002302192B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002302192A AU2002302192B2 (en) 2001-06-13 2002-06-11 Treatment and composition for wound healing

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
AUPR5637 2001-06-13
AUPR5637A AUPR563701A0 (en) 2001-06-13 2001-06-13 Treatment and composition for wound healing
AUPS1433 2002-04-02
AUPS1433A AUPS143302A0 (en) 2002-04-02 2002-04-02 Treatment and composition for wound healing
PCT/AU2002/000751 WO2002100445A1 (en) 2001-06-13 2002-06-11 Treatment and composition for wound healing
AU2002302192A AU2002302192B2 (en) 2001-06-13 2002-06-11 Treatment and composition for wound healing

Publications (2)

Publication Number Publication Date
AU2002302192A1 AU2002302192A1 (en) 2003-05-15
AU2002302192B2 true AU2002302192B2 (en) 2007-08-16

Family

ID=25646727

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002302192A Expired AU2002302192B2 (en) 2001-06-13 2002-06-11 Treatment and composition for wound healing

Country Status (8)

Country Link
US (3) US20040176288A1 (enExample)
EP (1) EP1404412B1 (enExample)
JP (1) JP4351041B2 (enExample)
AT (1) ATE550073T1 (enExample)
AU (1) AU2002302192B2 (enExample)
CA (1) CA2450240A1 (enExample)
ES (1) ES2384099T3 (enExample)
WO (1) WO2002100445A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2298338T1 (sl) 2002-09-16 2012-11-30 Agennix Inc Laktoferinski sestavki in postopki za zdravljenjekožnih ran
US7183381B2 (en) 2004-10-26 2007-02-27 Agennix, Inc. Composition of lactoferrin related peptides and uses thereof
US20080293631A1 (en) * 2005-01-07 2008-11-27 Christopher John Jackson Treatment for Autoimmune and Inflammatory Conditions
DK1853631T3 (en) * 2005-01-24 2016-03-29 Univ Texas Fc-FUSION CONSTRUCTIONS BINDING TO PHOSPHATIDYLSERINE AND THERAPEUTIC APPLICATION THEREOF
BRPI0613227A2 (pt) * 2005-06-09 2011-01-04 Chiang Chuan Chi uma composição para cicatrização de ferida e uso desta
WO2007075853A2 (en) * 2005-12-20 2007-07-05 Swiss-American Products, Inc. Protease compositions for the treatment of damaged tissue
GR1005700B (el) * 2006-09-01 2007-10-22 (40%) ����� �������� Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα
AR067345A1 (es) * 2007-07-10 2009-10-07 Paion Deutschland Gmbh Uso de trombomodulina para la preparacion de un medicamento trombolitico
EP2014296A1 (en) * 2007-07-10 2009-01-14 PAION Deutschland GmbH Novel strategies for increasing the reperfusion in obstructed blood vessel
GB2457965B8 (en) * 2008-07-01 2011-02-16 Renovo Ltd Methods and systems for determining efficacy of medicaments.
US20130259854A1 (en) * 2012-04-02 2013-10-03 Saint Louis University, A Non-Profit Organization Methods and compositions for reducing the incidence of post-surgical adhesions
CN104394883B (zh) * 2012-07-04 2017-05-31 悉尼大学 炎性皮肤病症的治疗
EP3137102B1 (en) * 2014-04-16 2021-07-14 ZZ Biotech LLC Apc for use in the treatment of abnormal cutaneous scarring
US20170035862A1 (en) * 2014-04-16 2017-02-09 Zz Biotech Llc Use of APC analogue for wound healing
TR202021285A1 (tr) * 2020-12-22 2022-07-21 Univ Yeditepe Yara skarinin önlenmesi̇ ve tedavi̇si̇nde kullanilmak üzere erbium borat i̇çeren formülasyon

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002172A1 (en) * 1992-07-24 1994-02-03 Oklahoma Medical Research Foundation Blockade of protein c activation reduces microvascular surgical blood loss
WO1995030429A1 (en) * 1994-05-04 1995-11-16 Board Of Trustees Of The University Of Arkansas Novel ophthalmologic uses of protein c
US5571786A (en) * 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
WO1999020293A1 (en) * 1997-10-20 1999-04-29 Eli Lilly And Company Methods for treating hypercoagulable states or acquired protein c deficiency

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197325B1 (en) * 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US5648380A (en) * 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
AT397615B (de) 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
US5279956A (en) * 1991-06-24 1994-01-18 The Scripps Research Institute Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C
US5583102A (en) * 1993-12-03 1996-12-10 University Of Iowa Research Foundation Human thrombomodulin in wound healing
JP3802104B2 (ja) 1995-05-31 2006-07-26 財団法人化学及血清療法研究所 脊髄損傷に伴う神経障害の予防・治療剤
SE9600216D0 (sv) * 1996-01-18 1996-01-18 Hans Arne Hansson Styrning av läkningsprocesser
JP3578627B2 (ja) * 1998-05-15 2004-10-20 株式会社ホギメディカル 創傷患部の治癒を促進する組織シーラント
CA2358492A1 (en) 1998-12-21 2000-06-29 Eli Lilly And Company Combination therapy for the treatment of sepsis
WO2001056532A2 (en) 2000-02-04 2001-08-09 The Scripps Research Institute Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
ES2242740T3 (es) * 2000-03-28 2005-11-16 Eli Lilly And Company Proteina c activada para el tratamiento de pancreatitis.
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571786A (en) * 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
WO1994002172A1 (en) * 1992-07-24 1994-02-03 Oklahoma Medical Research Foundation Blockade of protein c activation reduces microvascular surgical blood loss
WO1995030429A1 (en) * 1994-05-04 1995-11-16 Board Of Trustees Of The University Of Arkansas Novel ophthalmologic uses of protein c
WO1999020293A1 (en) * 1997-10-20 1999-04-29 Eli Lilly And Company Methods for treating hypercoagulable states or acquired protein c deficiency

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Annals of Surgery 232(2) (Aug 2002) pp 272-280 *
The Journal of Neuroscience 18(4) (Feb 1998) pp 1393-1398 *

Also Published As

Publication number Publication date
EP1404412A1 (en) 2004-04-07
US8728512B2 (en) 2014-05-20
CA2450240A1 (en) 2002-12-19
EP1404412A4 (en) 2006-03-01
EP1404412B1 (en) 2012-03-21
ATE550073T1 (de) 2012-04-15
US20040176288A1 (en) 2004-09-09
US20140219991A1 (en) 2014-08-07
ES2384099T3 (es) 2012-06-29
JP2004532892A (ja) 2004-10-28
US20130280234A1 (en) 2013-10-24
WO2002100445A1 (en) 2002-12-19
JP4351041B2 (ja) 2009-10-28
WO2002100445A8 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
US8728512B2 (en) Treatment and composition for wound healing
AU2002302192A1 (en) Treatment and composition for wound healing
JP2004532892A6 (ja) 傷治癒のための処置および組成物
US20080108551A1 (en) Treatment of wounds
AU2007266775B2 (en) Chymotrypsin from Lucilia sericata larvae and its use for the treatment of wounds
CN101541829A (zh) 来自丝光绿蝇的胰凝乳蛋白酶及其在治疗伤口中的用途
Scott et al. 051 Topical Oxygen Alters Angiogenesis‐Related Growth Factor Expression in Chronic Diabetic Foot Ulcers
US20110280858A1 (en) Treatment of wounds
Stechmiller et al. 052 Effect of Negative Pressure Wound Therapy on the Expression of TNF‐α, IL‐1β, MMP‐2, MMP‐3, and TIMP‐1 in Wound Fluid of Adults with Pressure Ulcers
Ennis et al. 036 MIST Ultrasound: The results of a multicenter, randomized, double‐blind, sham‐controlled trial of the healing of diabetic foot ulcers
Mooney et al. 031 Mechanical Characteristics of Fibroblast–Fibrin Constructs: Effect of Fibrinogen and Thrombin Concentration
Monroe et al. 075 Effect of Polyhydrated Ionogen (PHI) on Viability and Matrix Metalloproteinase Levels in Medium of Cultured Cells
Huemer et al. 022 Extracorporal Shock Wave is More Effective than Gene Therapy with TGF‐Beta to Reduce Ischemic Necrosis in a Rat Epigastric Skin Flap Model
Krötzsch et al. 055 A Comparative Evaluation of Maltodextrin/Ascorbic Acid Vs. Standard Care for the Treatment of Venous Leg Ulcers
Pirayesh et al. 054 The Efficacy of PolyHydrated Ionogens in Achieving Stable Wound Closure in Recalcitrant Diabetic Foot Ulcers: A Multicenter Phase 1 Pilot Study
Man et al. 065 Blockade of Rage with Lentiviral Gene Therapy Accelerates Healing in Diabetic Wounds Over Time
Ho et al. 072 Wound Healing Properties of Reconstituted Freeze‐Dried Platelets
Okwueze et al. 042 Role of Erbb3 and Epidermal Growth Factor‐Like Ligands on Wound Healing
Higgins 087 PAI‐1 Gene Expression in Wound‐Edge Keratinocytes is Upstream Stimulatory Factor‐Dependent and Required for Cell Migration
Guthrie 050 Amplification of the Hypoxic Wound Signal by Treprostinil Sodium (Remodulin®) as Measured by PeriWound Tcpo2 and Laser Doppler Signals
Sandulache et al. 048 Interleukin‐1β Regulates the Secretion of but not Expression of Receptors for Prostaglandin E2
Kong et al. 044 Up‐Regulated p38, PCNA, and Decreased Smooth Muscle Actin in Cyclophilin C‐Associated Protein Null Mice During Skin Wound Healing
Gajendrareddy et al. 020 Stress‐Induced Modulation of Matrix Metalloproteinases During Cutaneous Wound Repair
Lam et al. 080 The Effects of Papain‐Urea‐Copper Chlorophyllin Ointment on Healing of Wounds in an Acute Infected Full Thickness Porcine Model
Bodnar et al. 057 Activation of CXCR 3 Inhibits Endothelial Tube Formation Through the Modulation of M‐Calpain

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ZZ BIOTECH LLC

Free format text: FORMER OWNER WAS: THE UNIVERSITY OF SYDNEY

MK14 Patent ceased section 143(a) (annual fees not paid) or expired